Document is current
Any future updates will be listed below
-
Authors
Yin, Ariel C.
Holdcraft, Cayla J.
Helmig, Tyler J.
Brace, Eamonn J.
Suster, David I.
Shienbaum, Alan J.
Roden, Dylan
Kalyoussef, Evelyne
Mir, Ghayoour
Capitle, Eugenio
Baredes, Soly
Shanti, Rabie M.
Kaneko, Mika K.
Kato, Yukinari
Kobayashi, Hisataka
Furusawa, Aki
Fatahzadeh, Mahnaz
Goldberg, Gary S.
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP24am0521010 and JP24ama121008)
Intramural Research Program of the National Institutes of Health, National Cancer Institute (ZIA BC 011513)
Osteopathic Heritage Foundation
New Jersey Health Foundation (PC78-24NIH)
National Institutes of Health (1R15CA271044-01 and 1R41CA268160-01A1)
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 1 July 2025
First Online: 19 July 2025
Declarations
:
: The authors declare the following relationships which may be considered as potential competing interests: GSG has intellectual property and ownership in Sentrimed Inc. ACY and CJH have ownership and received financial support from Sentrimed Inc. which is developing agents including MASL that target podoplanin to treat diseases including cancer and arthritis. The other authors declare no conflicts of interest.
